| __timestamp | Celldex Therapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 12665000 |
| Thursday, January 1, 2015 | 4011000 | 20202000 |
| Friday, January 1, 2016 | 102026000 | 32407000 |
| Sunday, January 1, 2017 | 96171000 | 35219000 |
| Monday, January 1, 2018 | 66449000 | 36386000 |
| Tuesday, January 1, 2019 | 42672000 | 43081000 |
| Wednesday, January 1, 2020 | 42534000 | 39330000 |
| Friday, January 1, 2021 | 3068000 | 43283000 |
| Saturday, January 1, 2022 | 1400000 | 48316000 |
| Sunday, January 1, 2023 | 3008000 | 54634000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology and medical devices, understanding cost efficiency is crucial. Celldex Therapeutics, Inc. and MiMedx Group, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Celldex's cost of revenue peaked in 2014 at over 100 million, but by 2022, it plummeted to just 1.4 million, marking a dramatic decrease of nearly 99%. This suggests a significant shift in their operational strategy or market conditions. In contrast, MiMedx Group's cost of revenue steadily increased, reaching its highest in 2023 at approximately 54.6 million, a 331% rise from 2014. This growth could indicate expansion or increased production efficiency. These trends highlight the dynamic nature of cost management in the industry, offering insights into how companies adapt to market demands and operational challenges.
Cost of Revenue Trends: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Novo Nordisk A/S vs MiMedx Group, Inc.
Novartis AG vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Amgen Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and MiMedx Group, Inc.
Bio-Techne Corporation vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Wave Life Sciences Ltd. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.
Xencor, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored